This podcast examines the clinical utility of ctDNA-based MRD testing in diffuse large B-cell lymphoma, focusing on its role in post-treatment risk stratification, relapse detection, and treatment decision-making. Dr. David Russler-Germain reviews evidence showing that ctDNA MRD testing provides stronger prognostic value and earlier detection of recurrence than PET-CT imaging, supporting its growing integration into routine lymphoma care and NCCN-guided management.